Tetra Bio-Pharma to Present Key Research Findings as Part of Food and Drug Administration (FDA) Public Hearing on CBD
Momentum Public Relations
Press Releases: May 30th, 2019
Tetra Bio-Pharma Inc. (“Tetra” or the “Company”), a leader in cannabinoid-based drug discovery and development (TSX VENTURE: TBP) (OTCQB: TBPMF), will present key findings from its three Phase 1 and its Phase 2 cancer and non cancer investigational trials with cannabinoids, before the Food and Drug Administration’s (FDA) Scientific Data and Information about Products Containing Cannabis or Cannabis-Derived Compounds, Part 15 Public Hearing on Friday, May 31, 2019. The meeting will take place in Silver Spring, Maryland.
The goal of the hearing is to obtain additional scientific data and other information related to cannabis and cannabis-derived compounds to inform the FDA’s regulatory oversight of these products. This hearing is particularly important considering the passage of the Agriculture Improvement Act of 2018, Public Law 115-334 (so called Farm Bill), which, among other things, removed the plant Cannabis sativa L. or “hemp” from the Controlled Substances Act. Given the lack of safety evidence in the published literature, the FDA will hear from important stakeholders including patients, academia, manufacturing, retailers, public health and government bodies who will contribute by providing their data and experience. More than 400 different groups and entities made requests to present before the hearing.
Tetra’s presentation will be made by Rola Mazloum, Director of Regulatory Affairs and will comprise but not be limited to the following:
- Demonstrate that:
- inhalation via smoke or vapor achieves significantly superior delivery to the patient than the oral or sublingual routes;
- the oral route with capsules achieves less absorption than that of sublingual delivery;
- Provide a comparison of:
- side effects when given single dose versus repeat daily dosing.
- smoked versus vaped product;
- Present pertinent safety findings from the Phase 1 trials;
- Provide data that suggests a mechanism of tolerance to side effects;
- Present the impact of dose titration comparing smoked versus oral;
- Summarize the mycotoxin (fungi impurities) findings and how Tetra now manages this issue.
“The ground-breaking research that Tetra has and continues to advance is critical in adding to the scientific safety and efficacy data that regulators like the FDA, Health Canada and the European Medical Authority are looking for,” said Dr. Guy Chamberland, CEO and CSO of Tetra Bio Pharma. “Tetra is clearly seen as a world-class leader in conducting robust clinical studies, namely SERENITY© (Phase 3 in advanced cancer pain), REBORN© (phase 2 in breakthrough pain), OPIOSPARE© (Phase 2 to document opioid sparing effect) and others with cannabinoid-derived products to address unmet medical needs. We are privileged to share our insights and add to the body of evidence.”
About Tetra Bio-Pharma
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada authorized, and FDA reviewed, clinical trials aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.
For more information visit: www.tetrabiopharma.com
Source: Tetra Bio-Pharma
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
- Published in Life Sciences, Medical Marijuana, News Home, Tetra Bio Pharma
CROP Subsidiary Enters 5 Month CBD Isolate Supply Agreement With BIOSCIENCE ENTERPRISES, INC.
Momentum Public Relations
Press Releases: May 30th, 2019
CROP INFRASTRUCTURE CORP. (“CROP” or the “Company”) (CSE: CROP) (OTC: CRXPF) (Frankfurt: 2FR) announces today that ELITE VENTURES GROUP, LLC (“Elite”), a Nevada limited liability company in which CROP holds a 49% membership interest, in partnership with its licensee THE HEMPIRE COMPANY, LLC (“Hempire” and, together with Elite, “Elite & Hempire”), has entered into a supply agreement (the “Supply Agreement”) with BIOSCIENCE ENTERPRISES, INC. (“Bioscience”), a California based cannabidiol (“CBD”) isolate distribution company, to supply Bioscience with an aggregate of USD$89,500,000 in CBD isolate, with deliveries required to commence in November, 2019 and ending in March 2020, upon completion of the Supply Agreement’s initial five-month term (the “Initial Term”).
Pursuant to the terms of the Supply Agreement, Elite & Hempire have agreed to provide certain amounts of CBD isolate, on a monthly basis, to Bioscience on an agreed upon per kilogram price in consideration for:
- a USD$525,000 deposit payable upon entry of the Supply Agreement (paid);
- a second deposit of USD$350,000 due within thirty (30) days of entry of the Supply Agreement; and
- USD$875,000 due upon confirmation of the first Shipment (the “Third Deposit” and, collectively, the “Deposits”).
The Deposits are to be applied against the balance of first Shipment. In the event Elite & Hempire fail to deliver the first Shipment, Bioscience is entitled, at its sole discretion, to either the full repayment of the Third Deposit or have the proceeds of Third Deposit converted into common shares in the capital of CROP (each, a “Share”) at a price discounted 20% to the closing market price of the Shares on November 15, 2019, subject to a floor of $0.30 per Share.
Prior to each Shipment, Bioscience shall deposit 10% of the value of the CBD isolate of the subject Shipment (USD$1,900,000) into an escrow account held by Bioscience. The balance of each Shipment (USD$17,100,000) is due and payable within thirty (30) days of the receipt (“NET 30”), by the parties, of testing results for heavy metals, residuals, pesticides and microbial content in addition to a minimum 99.5% purity rating. The CBD isolate is to be sent for testing within three (3) business days of its delivery to Bioscience’s distribution center. During the NET 30 period, Elite & Hempire shall maintain title of the CBD isolate.
All proceeds generated from the sale of the CBD isolate to Bioscience under the Supply Agreement are to be distributed among the members of Elite pro rata to each members’ respective membership interest (approximately USD$43,855,000 for CROP’s 49% membership interest in Elite).
Bioscience has the sole right to extend the Initial Term for an additional two months (until May, 2020) on the same terms disclosed above (an additional USD$38,000,000 in value). The total anticipated value of the Supply Agreement, if the Initial Term is extended, is expected to be approximately USD$131,500,000.
Elite’s Nye County, Nevada CBD farm spans approximately 2,200 acres with 1,350 acres under pivot irrigation using organic growing methodologies. The 2019 cultivation is expected to produce 10-20% CBD genetic hemp-CBD which is expected to be extracted and isolated to produce a minimum 99.5% pure CBD isolate. Based on calculations of the Company’s grow consultant and assuming a minimum average of 10% CBD content, the Supply Agreement will represent ~35% of the farm’s potential CBD isolate yield from its 2019 cultivation. The parties plan to work together not just within the parameters of the Supply Agreement, but also to expand the Supply Agreement to include new high-yield cannabinol (“CBN”) and cannabigerol (“CBG”) isolates in order to provide new SKUs for Bioscience and to help foster a long-term partnership for the Company, its subsidiaries and stakeholders.
In connection with the Supply Agreement, CROP has agreed to pay an introduction fee of 1,333,333 Shares at a deemed price of CAD$0.30 per Share to a third party finder who introduced Elite & Hempire to Bioscience. All securities issued in connection with the Supply Agreement are conditional upon the approval of the Canadian Securities Exchange (“CSE”) and will be subject to a statutory hold period of four months and a day.
Richard Parker, President of Bioscience stated: “We are thrilled to be working with such an innovative group as CROP on a partnership that we hope will flourish within the progressing CBD industry. Having the best products on the market is what we believe makes Bioscience stand out as a reputable supplier, and without producers like CROP that would not be possible.”
Michael Yorke, CEO of CROP stated: “While the monetary value of the Supply Agreement is significant for CROP and its stakeholders, the relationship we are building with the team at Bioscience is key to our continual efforts to become a key player in the CBD production space and the development of new strains of product for isolation which will complement Bioscience’s industry-leading clientele and what both Bioscience and CROP believe will be in demand in 2020, 2021 and far beyond.”
About Bioscience
Since its inception in 2018, Bioscience has emerged as a major contender in the CBD supply business. Native to California, Bioscience has contracts across the continental USA and Canada for the supply of European Union and domestic grade isolate, oil and aerosol CDB in white label or specialized labeled products. Bioscience prides itself on having the purest CBD supply on the market today brought through a world class quality assessment and quarantine process.
About CROP
CROP is a publicly listed company trading on the CSE under the symbol CROP. The Company is focused on owning a portfolio of cannabis branding, CBD and real estate assets through its wholly and partially-owned subsidiaries. CROP’s portfolio of projects includes cultivation properties in California, two in Washington State, a 1,000-acre Nevada cannabis farm, 2,115 acres of Hemp CBD farms, and a growing portfolio of share equity in various companies within the cannabis space.
CROP has developed a portfolio of assets including Canna Drink, a cannabis infused functional beverage line and 16 cannabis brands.
Company Contact
Michael Yorke – CEO and Director
E-mail: info@cropcorp.com
Website: www.cropcorp.com
Phone: (604) 484-4206
- Published in Cannabis, CBD, CROP Infrastructure, Marijuana, News Home
IAMGOLD Intersects 56.46 g/t Au Over 6 Metres Including 1.5 Metre Grading 224 g/t Au on Nelligan
Momentum Public Relations
Press Releases: May 30th, 2019
The management of Vanstar Mining Resources Inc. (VSR-TSX-V) is very pleased to announce the first results from the 2019 winter drilling campaign carried out by its strategic partner IAMGOLD Corporation. This program, with a total of 17,654 meters of drilling in 50 holes, was aimed at 1) delimit the northern limit of the Renard deposit 2) complete in the definition of a geological model in order to calculate a first gold resource in place and 3) check its extension towards west. These three goals have all been achieved.
The following table shows the main significant results from drill holes NE-19-100 to NE-19-121. The results from the 28 other drill holes will be published as soon as available.
• | RENARD ZONE : | |
• | Hole NE-19-102: | 37.09 metres grading 1.81 g/t Au |
Including | 9.81 metres grading 2.73 g/t Au | |
• | Hole NE-19-103: | 23.80 metres grading 2.20 g/t Au |
Including | 3.75 metres grading 5.92 g/t Au | |
Including | 5.30 metres grading 3.92 g/t Au | |
Including | 2.00 metres grading 8.20 g/t Au | |
• | Hole NE-19-105: | 26.15 metres grading 1.69 g/t Au |
Including | 9.15 metres grading 3.68 g/t Au | |
Including | 1.35 metres grading 10.85 g/t Au | |
And | 41.60 metres grading 1.18 g/t Au | |
Including | 15.10 metres grading 2.12 g/t Au | |
• | HoleNE-19-108: | 37.43 metres grading 1.32 g/t Au |
Including | 11.01 metres grading 2.40 g/t Au | |
And | 11.00 metres grading 2.56 g/t Au | |
And | 73.00 metres grading 1.09 g/t Au | |
• | Hole NE-19-113: | 11.20 metres grading 3.39 g/t Au |
Including | 3.60 metres grading 7.65 g/t Au | |
And | 6.00 metres grading 56.49 g/t Au ( 7.99 g/t Au capped @ 30 gt ) | |
Including | 1.50 metres grading 224 g/t Au | |
• | Hole NE-19-114: | 16.70 metres grading 4.04 g/t Au ( 3.53 g/t Au capped @ 30 gt ) |
Including | 7.73 metres grading 7.02 g/t Au | |
Including | 1.00 mètre grading 38.50 g/t Au | |
And | 28.42 metres grading 2.11 g/t Au | |
Including | 5.00 metres grading 7.05 g/t Au | |
And | 45.85 metres grading 1.04 g/t Au | |
Including | 3.67 metres grading 3.85 g/t Au | |
And | 9.00 metres grading 1.55 g/t Au | |
And | 22.50 metres grading 1.04 g/t Au | |
• | Hole NE-19-116: | 5.55 metres grading 14.95 g/t Au ( 8.06 g/t Au capped @ 30 gt ) |
Including | 1.30 metres grading 59.40 g/t Au | |
• | Hole NE-19-118: | 46.80 metres grading 1.59 g/t Au |
Including | 6.67 metres grading 5.96 g/t Au | |
And | 26.90 metres grading 1.16 g/t Au | |
And | 25.73 metres grading 1.08 g/t Au | |
• | Hole NE-19-120: | 10.50 metres grading 2.11 g/t Au |
Including | 4.00 metres grading 3.94 g/t Au | |
And | 11.75 metres grading 1.99 g/t Au | |
Including | 6.00 metres grading 2.70 g/t Au |
( See the diamond drill location map in annexe )
« We are totally satisfied with these news results. These show a consistent auriferous presence in the extensive Renard hydrothermal system and it is also encouraging to see that it remains open in its western extension. Hole NE-19-120 demonstrates this well » commented the CEO and President of the Company, Mr. Guy Morissette
In a separate press release on the recent results Craig MacDougall, Senior Vice President, Exploration for IAMGOLD, stated: “The 2019 drilling program has successfully confirmed wide zones of mineralization extending to surface, which will help complete our deposit model in support of a mineral resource estimate planned for completion in the second half of the year. It is important to note that the mineralized zones remain open and are therefore believed to have favourable potential to continue to expand with additional drilling. I commend the efforts of our exploration team and contractors, who continued to advance this grassroots discovery successfully and – most importantly – safely in the difficult winter conditions of this region of Quebec.”
The 2019 diamond drilling program was designed to infill and further test continuity of the mineralized zones of the Renard mineralized system, located immediately north of the previously known Liam and Dan zones. It specifically targeted the shallower part of this wide mineralized corridor to confirm and define its limit closer to the surface. Most of the holes intersected the expected zones of hydrothermal alteration characterized by variable carbonatization, sericite, phlogopite and pervasive silicification affecting the hosting meta-sedimentary sequence. Associated mineralization consists of widespread disseminated pyrite, varying from 1% to locally 15%. Trace molybdenite and occasionally fine grains of visible gold are also observed.
Next Steps
Assay results from the remaining 28 drill holes totaling 10,680 metres will be reported once they are received, validated and compiled. Once in hand, the data from the 2019 drilling program, coupled with ongoing geological, geochemical and structural studies, will be integrated to support the development and refinement of a deposit model with the objective of completing an initial NI 43-101 compliant resource estimate in 2019 and will support the planning of future drilling programs.
About the Nelligan Project
The Nelligan project is underlain by a portion of the Caopatina segment belonging to the North Volcanic Zone of the Abitibi Belt of the Superior Province. The property is centered on the E-W Druillette synclinal with sediments of the Caopatina Formation bounded to the north and to the south by volcanic rocks of the Obatogamau Formation. The North and South portions of the property are occupied by granodioritic to tonalitic intrusions. The project is transected by numerous regional and local structures and deformation zones which can be important in the localization of gold mineralization.
Gold showings of the area can be grouped according to their style of mineralization: Quartz-sulphide vein type mineralization and disseminated pyrite mineralization. On the local scale, the Nelligan project contains several interesting gold showings, including the Liam and Dan Zones discovered by drilling in 2013 and 2014, and the historical Lake Eu showing. Significant alteration and associated gold mineralization was intersected over wide intervals to the north of the known gold showings over a strike length of more than 1.0 kilometre, to a depth of over 350 vertical metres (Zones 36 and Renard). These prospective showings appear to fall within a structural corridor with a potential strike length of several kilometres associated to the Guercheville Deformed Corridor located 5 kilometres north of the property.
The Nelligan Project is held under an earn-in option to joint venture agreement with Vanstar. The Company holds an undivided 51% interest in the property, and holds an option to earn a further 24% undivided interest in exchange for cash payments totaling C$2,750,000 to Vanstar and the delivery of an NI 43-101 compliant Resource Estimate and Technical Report before March 2022. Once vested to an undivided 75% interest, IAMGOLD will have a further option to acquire an additional interest of 5%, to hold an 80% interest in the Nelligan project by completing and delivering a Feasibility Study. Vanstar would then retain a 20% undivided non-contributory carried interest until the commencement of commercial production, after which: (1) the 20% undivided interest becomes participating; and (2) Vanstar will pay its attributable portion of the total development and construction costs to the commencement of commercial production from 80% of its share of any ongoing distributions from the Joint Venture. Vanstar will also retain a 1% NSR royalty on selected claims of the project.
Table 1 Nelligan Project Drilling Results – 2019 Drilling program | ||||||||||||
Hole No. | UTM NAD83 Zone18 | AZ | DIP | EOH | from | To | Interval | True Width (1) | Au (2) (3) | NOTE | ||
Easting | Northing | Elevation | (°) | (°) | (m) | (m) | (m) | (m) | (m) | (g/t) | ||
NE-19-100 | 522592.86 | 5473859.92 | 375.68 | 330.00 | -50.00 | 447.00 | 98.76 | 109.50 | 10.74 | 8.80 | 0.64 | RENARD ZONE |
115.50 | 132.20 | 16.70 | 14.46 | 1.40 | ||||||||
156.95 | 176.25 | 19.30 | 15.81 | 1.01 | ||||||||
281.50 | 287.10 | 5.60 | 4.59 | 1.00 | ||||||||
NE-19-101 | 523165.25 | 5474067.60 | 371.18 | 330.00 | -50.00 | 300.00 | 129.00 | 155.90 | 26.90 | 17.29 | 0.56 | |
Including (3) | 149.00 | 149.98 | 0.98 | 0.63 | 4.51 | |||||||
NE-19-102 | 522631.36 | 5473897.09 | 375.11 | 330.00 | -47.00 | 375.00 | 87.12 | 96.31 | 9.19 | 8.64 | 0.92 | RENARD ZONE |
Including (3) | 87.12 | 91.50 | 4.38 | 4.12 | 1.34 | |||||||
116.42 | 153.51 | 37.09 | 30.38 | 1.81 | ||||||||
Including (3) | 116.42 | 123.17 | 6.75 | 5.85 | 2.82 | |||||||
Including (3) | 126.91 | 129.92 | 3.01 | 2.47 | 3.80 | |||||||
Including (3) | 141.69 | 151.50 | 9.81 | 8.04 | 2.73 | |||||||
164.83 | 179.46 | 14.63 | 9.40 | 0.58 | ||||||||
192.30 | 200.20 | 7.90 | 6.47 | 1.05 | RENARD ZONE | |||||||
223.40 | 232.00 | 8.60 | 6.59 | 0.61 | ||||||||
NE-19-103 | 522657.68 | 5473952.98 | 372.48 | 330.00 | -50.00 | 280.00 | 31.50 | 55.30 | 23.80 | 19.50 | 2.20 | RENARD ZONE |
Including (3) | 31.50 | 35.25 | 3.75 | 2.87 | 5.92 | |||||||
Including (3) | 50.00 | 55.30 | 5.30 | 4.06 | 3.92 | |||||||
Including (3) | 52.30 | 54.30 | 2.00 | 1.73 | 8.20 | |||||||
74.89 | 99.43 | 24.54 | 21.25 | 0.87 | ||||||||
149.00 | 155.62 | 6.62 | 5.42 | 1.21 | ||||||||
NE-19-104 | 523112.39 | 5474053.92 | 375.25 | 330.00 | -50.00 | 330.00 | 125.88 | 128.88 | 3.00 | 2.30 | 2.72 | |
249.00 | 256.50 | 7.50 | 5.75 | 0.88 | ||||||||
NE-19-105 | 522706.88 | 5473971.67 | 373.47 | 330.00 | -50.00 | 252.00 | 34.55 | 60.70 | 26.15 | 20.03 | 1.69 | RENARD ZONE |
Including (3) | 39.00 | 48.15 | 9.15 | 7.01 | 3.68 | |||||||
Including (3) | 39.00 | 40.35 | 1.35 | 1.03 | 10.85 | |||||||
84.85 | 126.45 | 41.60 | 29.42 | 1.18 | ||||||||
Including (3) | 84.85 | 99.95 | 15.10 | 11.57 | 2.12 | |||||||
NE-19-106 | 522677.57 | 5474033.47 | 372.02 | 330.00 | -50.00 | 225.00 | 50.75 | 83.10 | 32.35 | 24.78 | 0.64 | |
NE-19-107 | 523048.22 | 5474068.97 | 379.72 | 330.00 | -50.00 | 285.00 | No significant results | |||||
NE-19-108 | 522783.82 | 5473927.48 | 378.41 | 330.00 | -47.00 | 330.00 | 55.07 | 92.50 | 37.43 | 32.42 | 1.32 | RENARD ZONE |
Including (3) | 78.35 | 89.36 | 11.01 | 8.18 | 2.40 | |||||||
98.50 | 109.50 | 11.00 | 9.53 | 2.56 | ||||||||
Including (3) | 104.50 | 105.09 | 0.59 | 0.51 | 13.35 | |||||||
120.50 | 193.50 | 73.00 | 63.22 | 1.09 | ||||||||
NE-19-109 | 522722.43 | 5474048.83 | 372.84 | 330.00 | -45.00 | 177.00 | No significant results | |||||
NE-19-110 | 523080.28 | 5474115.31 | 378.87 | 330.00 | -50.00 | 222.00 | 45.00 | 67.50 | 22.50 | 15.91 | 0.53 | |
NE-19-111 | 522826.15 | 5474066.66 | 379.35 | 330.00 | -50.00 | 168.00 | No significant results | |||||
NE-19-112 | 522972.95 | 5474110.40 | 381.63 | 330.00 | -50.00 | 174.00 | 52.50 | 60.00 | 7.50 | 4.82 | 1.25 | |
NE-19-113 | 522820.17 | 5473971.36 | 377.87 | 330.00 | -50.00 | 312.00 | 38.95 | 50.15 | 11.20 | 9.70 | 3.39 | RENARD ZONE |
Including (3) | 40.00 | 43.60 | 3.60 | 3.12 | 7.65 | |||||||
56.20 | 63.14 | 6.94 | 6.01 | 1.07 | ||||||||
106.00 | 149.00 | 43.00 | 35.22 | 0.74 | RENARD ZONE | |||||||
Including (3) | 106.00 | 118.68 | 12.68 | 10.39 | 0.95 | |||||||
Including (3) | 124.00 | 129.00 | 5.00 | 4.10 | 1.29 | |||||||
Including (3) | 134.00 | 149.00 | 15.00 | 11.49 | 0.75 | |||||||
164.00 | 170.00 | 6.00 | 4.24 | 1.02 | ||||||||
182.00 | 188.00 | 6.00 | 4.24 | 56.49 (7.99 capped @ 30 g/t) | ||||||||
Including (3) | 185.00 | 186.50 | 1.50 | 1.06 | 224 | |||||||
NE-19-114 | 523109.04 | 5473743.37 | 372.87 | 330.00 | -49.00 | 552.00 | 128.64 | 143.55 | 14.91 | 12.91 | 0.56 | |
238.00 | 254.70 | 16.70 | 14.46 | 4.04 (3.53 capped @ 30 g/t) | RENARD ZONE | |||||||
Including (3) | 246.00 | 253.73 | 7.73 | 6.69 | 7.02 | |||||||
Including (3) | 247.00 | 248.00 | 1.00 | 0.87 | 38.50 | |||||||
281.25 | 309.67 | 28.42 | 24.61 | 2.11 | ||||||||
Including (3) | 302.80 | 307.80 | 5.00 | 4.33 | 7.05 | |||||||
326.15 | 372.00 | 45.85 | 41.55 | 1.04 | ||||||||
Including (3) | 332.53 | 336.20 | 3.67 | 3.18 | 3.85 | |||||||
427.50 | 436.50 | 9.00 | 7.79 | 1.55 | ||||||||
507.70 | 530.20 | 22.50 | 19.49 | 1.04 | ||||||||
NE-19-115 | 522857.82 | 5474007.58 | 381.27 | 330.00 | -50.00 | 279.00 | 87.00 | 127.28 | 40.28 | 28.48 | 1.04 | RENARD ZONE |
NE-19-116 | 522900.21 | 5474027.23 | 383.17 | 330.00 | -50.00 | 255.00 | 61.40 | 65.60 | 4.20 | 3.22 | 1.65 | RENARD ZONE |
80.50 | 86.05 | 5.55 | 4.25 | 14.95 (8.06 capped @ 30 g/t) | ||||||||
Including (3) | 81.80 | 83.10 | 1.30 | 1.00 | 59.40 | |||||||
91.90 | 105.80 | 13.90 | 10.65 | 0.50 | ||||||||
114.00 | 131.35 | 17.35 | 13.29 | 0.65 | ||||||||
174.00 | 193.00 | 19.00 | 13.44 | 0.73 | ||||||||
NE-19-117 | 523106.60 | 5473956.03 | 372.61 | 330.00 | -50.00 | 402.00 | 65.25 | 69.50 | 4.25 | 3.85 | 1.33 | |
105.50 | 114.50 | 9.00 | 5.79 | 0.98 | ||||||||
187.55 | 196.50 | 8.95 | 7.75 | 0.67 | RENARD ZONE | |||||||
202.30 | 211.13 | 8.83 | 6.76 | 0.81 | ||||||||
230.00 | 237.30 | 7.30 | 5.59 | 1.19 | ||||||||
NE-19-118 | 522965.30 | 5473908.54 | 379.44 | 330.00 | -50.00 | 372.00 | 57.00 | 59.10 | 2.10 | 1.82 | 2.73 | RENARD ZONE |
120.00 | 166.80 | 46.80 | 40.53 | 1.59 | ||||||||
Including (3) | 138.83 | 145.50 | 6.67 | 5.78 | 5.96 | |||||||
202.00 | 228.90 | 26.90 | 23.30 | 1.16 | ||||||||
Including (3) | 208.62 | 215.00 | 6.38 | 5.53 | 2.50 | |||||||
268.77 | 294.50 | 25.73 | 22.28 | 1.08 | ||||||||
Including (3) | 291.50 | 294.50 | 3.00 | 2.60 | 3.57 | |||||||
306.50 | 308.00 | 1.50 | 1.30 | 6.84 | ||||||||
NE-19-119 | 523031.45 | 5473994.43 | 377.61 | 330.00 | -50.00 | 381.00 | 175.50 | 180.72 | 5.22 | 4.28 | 1.64 | RENARD ZONE |
230.34 | 234.50 | 4.16 | 3.60 | 1.47 | ||||||||
NE-19-120 | 522341.5 | 5473691.7 | 370.0 | 330.00 | -50.00 | 552.00 | 243.00 | 253.50 | 10.50 | 6.75 | 2.11 | RENARD ZONE |
Including (3) | 245.00 | 249.00 | 4.00 | 2.57 | 3.94 | |||||||
342.75 | 354.50 | 11.75 | 9.00 | 1.99 | ||||||||
347.00 | 353.00 | 6.00 | 4.60 | 2.70 | ||||||||
365.00 | 384.50 | 19.50 | 14.94 | 1.09 | ||||||||
408.53 | 454.75 | 46.22 | 35.41 | 0.73 | ||||||||
NE-19-121 | 522970.64 | 5474004.50 | 383.17 | 330.00 | -48.00 | 300.00 | 123.80 | 145.12 | 21.32 | 16.33 | 0.61 | |
168.43 | 177.06 | 8.63 | 6.61 | 0.71 | RENARD ZONE |
Notes:
- True widths are estimated at 70 to 94% of the core interval.
- Drill hole intercepts are calculated with a lower cut of 0.50 g/t Au and may contain lower grade interval of up to 5 metres in length. They are generally reported with a minimum g*m (or Metal factor) of 5.
- Assays intervals are reported uncapped and capped at 30 g/t Au and high grade sub-intervals are highlighted.
Gilles Laverdière is considered a “Qualified Person” for the purposes of National Instrument 43-101 with respect to the technical information being reported on.
The TSX Venture Exchange and its Regulation Services Provider (as that term is defined in the TSX Venture Exchange Policies) do not accept any responsibility for the truth or accuracy of its content.
Source :
Guy Morissette
CEO Vanstar Mining Resources Inc.
gmvanstar@gmail.com
819-763-5096
www.vanstarmining.com
- Published in Mining, News Home, Vanstar Mining
Sirona Biochem Reports Excellent Preliminary Safety Assessment of Lead Anti-Wrinkle Compound LIP-01
Momentum Public Relations
Press Releases: May 28th, 2019
Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (“Sirona“) is pleased to announce safety testing on its lead glycoprotein compound in the anti-wrinkle program yielded excellent results and the company will immediately move to the next steps of development. This project was generously supported by BPI France and the region Haute Normandie.
The comprehensive safety analysis was performed by CEHTRA (www.cehtra.com), cosmetic toxicology specialists in Paris, France. Key in vitro measures and in silico analyses of safety were evaluated, including skin irritation, skin sensitization, ocular tolerability, phototoxicity, genotoxicity and carcinogenicity. It was concluded that there is no evidence of these issues in the testing. Also, based on in silico analysis, no systemic toxicity is expected.
“These are very encouraging results for our anti-wrinkle program. Sirona’s scientists at our French subsidiary, TFChem, will be focusing their efforts on the next set of tests and a detailed project plan to make this a priority. There is still work to be done in the lab, but we have nicely de-risked the project by conducting these safety assays”, reports Dr. Howard Verrico, CEO of Sirona Biochem.
Next steps in the program will include additional in vitro assays for a second review by CEHTRA to determine dosing. This will be followed by synthetic process refinements, synthesis of a batch for formulation, skin permeation study and clinical safety evaluation.
Loss of elasticity and degradation of fat tissue are two markers seen in aging skin, leading to the appearance of lines and wrinkles. Compounds that increase the number and volume of adipocytes (fat cells) can act as plumping, volumizing, and densifying skin agents, thereby reducing the visibility of wrinkle and potentially providing a more youthful look. Novel solutions are actively being sought out by the dermatology industry to address this.
The global anti-aging market is forecast to reach up to US$271.0 Billion by 2024.1 The anti-wrinkle product category held the largest share in the anti-aging market, with 59.3% contribution in 2017.2
The anti-wrinkle potential of LIP-01 is as a non-invasive treatment for fine wrinkles by a mechanism very different from dermal fillers and Botox®. Botox®3 is generally limited to use on the upper third of the face, specifically the frown lines between the eyebrows. Botox® also requires administration by a properly trained professional.
“Less of our team’s resources are needed on the skin lightening project as its development is now mainly focused on manufacturing. We are excited to have the opportunity to continue expanding the powerful technology platform developed by our Chief Scientific Officer Dr. Geraldine Deliencourt and her team. This anti-wrinkle compound has fascinating properties in cells and we anticipate moving it along quickly. If clinically successful, LIP-01 could exceed Botox in market potential,” Dr. Verrico concluded.
_______________________________ |
|
1 |
|
2 |
|
3 |
BOTOX COSMETIC® is a registered trademark of Allergan Inc. |
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
———————————————
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.
SOURCE Sirona Biochem Corp.
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/May2019/28/c1000.html
Contact:
regarding this press release, please contact: Jonathan Williams, Managing Director, Momentum PR, Phone: 1.450.332.6939, Email: jwilliams@momentumpr.com
- Published in Life Sciences, News Home, Sirona Biochem
SGS Produces 539 Ounces Per Ton Silver Flotation Concentrate From Canada Cobalt Castle Mine Tailings
Momentum Public Relations
Press Releases: May 24th, 2019
Canada Cobalt Works Inc. (TSXV: CCW) (OTC: CCWOF) (Frankfurt: 4T9B) (the “Company” or “Canada Cobalt”) is pleased to announce that metallurgical testwork performed by SGS Lakefield has demonstrated that historic stamp mill tailings at Canada Cobalt’s Castle mine are amenable to flotation and leaching, enhancing potential recoveries and creating an opportunity for a direct shipping precious metal concentrate in addition to a Re-2OX cobalt sulphate.
Highlights:
- SGS has produced a high purity flotation silver concentrate grading 18,486 grams per tonne(539.17 ounces per ton);
- Optimization is expected to increase the 70% recovery rate;
- Ontario is “Open For Business”: Through its engineering partner, Canada Cobalt is working closely and productively with the Ministry of Northern Development and Mines to quickly secure an amendment to the company’s existing advanced exploration permit to allow the proposed tailings program to proceed (refer to March 1, 2019, news release).
Castle Tailings Amenable to Flotation
Through a flotation test, SGS has taken a gravity concentrate of a 120-kilogram sample from the Castle mine’s historic tailings pond with a calculated head assay of 459 g/t silver and has created a high purity flotation concentrate grading 18,486 g/t with an initial recovery of 70%.
Given these results, Canada Cobalt is immediately taking a much larger sample from the tailings for SGS to create another flotation concentrate including a cobalt concentrate. The aim of the proposed tailings program is to produce a high purity direct shipping precious metal concentrate (silver and gold), while Canada Cobalt’s proprietary Re-2OX Process would be used to convert a cobalt concentrate into a cobalt sulphate.
Quality Assurance/Quality Control
Sample material was derived using flotation processes from the concentrate of a 120-kilogram sample from the Castle mine’s historic tailings pond that was randomly collected in pails and subsequently transported by courier to SGS Laboratories, an accredited lab in Lakefield, Ontario. These samples were submitted for fire assay for silver with atomic absorption finish.
Qualified Person
The technical information in this news release was prepared under the supervision of Frank J. Basa, P. Eng., Canada Cobalt’s President and Chief Executive Officer, who is a member of Professional Engineers Ontario and a qualified person in accordance with National Instrument 43-101.
About Canada Cobalt Works Inc.
Canada Cobalt is focused on immediate and longer-term value drivers at its past producing Castle mine and adjoining land package in the historic Northern Ontario Silver-Cobalt district, Canada’s cobalt heartland since the start of the electric vehicle revolution. The Canada Cobalt “advantage” includes underground access at Castle, an innovative tailings program with a plan to recover silver, gold and cobalt, a recently installed pilot plant to produce gravity concentrates on site, a proprietary hydrometallurgical process known as Re-2OX, and exciting exploration discovery potential at Castle East.
“Frank J. Basa”
Frank J. Basa, P. Eng.
President and Chief Executive Officer
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This news release may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming work programs, geological interpretations, receipt of property titles, potential mineral recovery processes, etc. Forward-looking statements address future events and conditions and therefore, involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements.
SOURCE Canada Cobalt Works Inc.
View original content: http://www.newswire.ca/en/releases/archive/May2019/24/c4908.html
- Published in Canada Cobalt Works, Mining, News Home
Sirona Biochem Hires Contract Research Organization for Manufacturing Process Optimization for TFC-1067
Momentum Public Relations
Press Release: May 22, 2019
Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (“Sirona“) is pleased to announce it has commissioned Contract Research Organization (CRO) Roowin (www.roowin.com) to develop the final chemical process required for large scale manufacturing of TFC-1067. This is another important step in the commercialization of Sirona’s novel skin lightening agent.
Sirona anticipates the need for multiple kilogram production of TFC-1067 in the short term and is therefore taking this necessary intermediate step. Sirona will then proceed to manufacture an inventory of TFC-1067 of up to 20 kilograms to be ready for anticipated orders. Due to the high potency of the compound, each kilogram will supply Sirona’s active skin lightening ingredient to produce ten thousand consumer size (fifty milliliters) containers of finished product.
“The chemistry of TFChem (Sirona’s subsidiary) is unique and our science team has an excellent understanding of this chemistry. We have already successfully worked on production of TFC-1067 at the kilogram scale,” reports Patrice Rool, CEO of Roowin. “Our scientists will collaborate with TFChem to develop the most efficient final process to manufacture TFC-1067. We are very excited to be a part of the ongoing development of this innovative skin lightener.”
“Roowin’s expertise in manufacturing process development will move TFC-1067 closer to final commercialization. In addition, our scientists at TFChem have developed new chemistry that will further improve manufacturing efficiencies and lower cost of goods,” Dr. Verrico concluded. “The new manufacturing process for TFC-1067 we anticipate will be used at manufacturing sites globally down the road. Roowin has extensive experience with our chemistry and we are excited to be working together again.”
About Roowin
Roowin is a privately-owned Contract Research Organization (CRO) headquartered in Riom (Auvergne), France. Its core business being in high value-added fine chemistry, Roowin offers a large range of chemical services. Roowin supports customers and partners to advance their drug candidates from early research phase up to licensing out API in phase II or to the Market for small batches, about 20 kilograms.
Roowin is accredited ISO 9001. Roowin’s facilities include cGMP facilities: Kilo-laboratory / Pilot plant. Roowin can accompany its customers from early lead optimization through scale-up and small-scale GMP synthesis up to medium scale GMP manufacturing.
For more information, please visit www.roowin.com.
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary platform technology. Sirona specializes in stabilizing carbohydrate molecules with the goal of improving efficacy and safety. New compounds are patented for maximum revenue potential.
Sirona’s compounds are licensed to leading companies around the world in return for licensing fees, milestone fees and ongoing royalty payments. Sirona’s laboratory, TFChem, is in France and is the recipient of multiple French national scientific awards and European Union and French government grants. For more information, please visit www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem’s forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem’s business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.
SOURCE Sirona Biochem Corp.
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/May2019/22/c5079.htmlv
- Published in Bio technology, Life Sciences, News Home, Sirona Biochem
Crystal Lake Mining – A Golden Team
Momentum Public Relations
Original Source: Junior Gold Report
I have been in the junior mining field writing my newsletter for over eighteen years. During that time, I have met a whole assortment of people and I’ve seen my share of arrogant so-called leaders. I’ve been on the ego see-saw, trying to balance out what the actual story is versus whatever nonsense the guy either on the top or in the IR department is trying to sell me. I am one that always tries to see the goodness in people.
Fortunately, I have learned a bit or two about the poker hands people try to represent, but as we all do, I still get bluffed. The key is recognizing the bluffers from the winners which is tricky to do in any poker game, let alone in junior mining.
Along comes Crystal Lake Mining (TSXV: CLM) and the see-saw starts to balance – very refreshing. Some weeks ago, when the company’s stock was trading around .30/share, I alerted my readers that I would be initiating coverage. Crystal Lake is a junior exploration company based in British Columbia with one of the largest land packages in the red hot Eskay district in the heart of the famous Golden Triangle region.
Recently, I was invited along with many members of the team to Vancouver to network and attend the presentation. I have always found that direct experience is a better way to judge how a company operates than merely considering what I’ve been told in a phone call or what’s on the internet. That is why with every sponsor/client, I insist on spending time with management and seeing the property.
The Crystal Lake team led by Richard Savage, President/CEO is an inclusive, genuine team who are down-to-earth and all-around a great group to be involved with. There was no poker face, they showed their hand right on the flop.
Richard started his career as an Investment Advisor in Yorkton Securities which later became Richardson GMP, remaining there for 28 years. Based on the time I spent with Richard, I believe him to be a man of commitment and integrity. His passion for children charities really reflects the kind of person that he is. We spoke at great length about the importance of giving back and how we can help each other’s causes in helping others.
The event in Vancouver was top-notch. Around 50 people attended the four-hour very informative Saturday morning presentation. There were various other networking activities, all planned and carried out with precision.
They have a real winner heading up Investor Relations in Sean Kingsley whom I’ve known for many years. He is on the cover of Public Entrepreneur, Special PDAC Edition as one of the New Faces of Mining. He brings a vast amount of investor relations experience and he lives and breathes mining.
The junior mining industry is very intricate, like a giant jigsaw puzzle where all the pieces have to connect in just the right way. It took me many years to figure out how a whole mining project is connected and am still learning. Yes location is key, but you also have to look at the operations behind the drilling and exploration and you need to consider the team as a whole – the management, drillers, geologists, marketing team etc.
In their property negotiations, Crystal Lake obtained what seems to be a stellar deal, in particular, with the Newmont Lake project in the Golden Triangle Region, which seems to be the most intriguing project out of the three main ones that Crystal Lake is currently managing.
According to Dr. Peter C. Lightfoot, Technical Advisor for Crystal Lake,
“There are vast tracts of unexplored and underexplored ground within the Newmont Lake Project to feed an already large pipeline of quality targets rarely seen on one property. This has me and our discovery team extremely excited for 209.1”[1]
Investors always hope for a royal flush type of a hole, but one mammoth hole is usually not a determinant of a long-term successful drill program. You have to have a series of successful holes that show the potential advancement of the project.
In initial drilling undertaken at Burgundy Ridge (part of the Newmont project) in the fall of 2018, the holes suggest that there exists intervals of copper-rich mineralization with gold and silver.
Drilling should commence in early summer after the snow melts, but of course, Mother Nature may have some say in this.
No matter what cards Crystal Lake is holding, the investors should not be bored as they await the drill results.
Currently, resource stocks are not considered sexy as they were in 2010/2011. A big discovery could very well change that. The potential is here which would make Justin Timberlake proud.
In the next little while, I expect to be putting on my stomping boots again and visiting the project.
In summary, I will say this. It is easy to criticize but it can be hard to praise – especially when praise is called for. In my case, some of this comes from my experiences of rarely meeting a President who actually listens and puts the team first. In fact, I’m pretty used to being introduced/speaking with President’s who feel like they know-it-all, when their hold cards are just a deuce and seven. Richard Savage exemplifies the complete opposite of this and any company that knows its’ worth would be wise to follow his directorial method.
I took away from my time in Vancouver that Crystal Lake has compiled a great team of people and that their interest for the stockholders seems to be a genuine priority. That integrity along with a phenomenal exploration plan and the right experts, in my opinion, is a recipe for potential high success.
To be rewarded in buying mining shares, it is generally prudent to invest before the drill results are released on a property with amazing potential. Although no one can guarantee the performance of any stock, the risk reward ratio seems to be favourable in this particular case.
I know a good possibility when I see it. Some have even listened to me. With cautious optimism and great enthusiasm, I am involved with Crystal Lake Mining that has one of the best management teams I have ever seen along with one of the best stories I have heard in many years. They seem to be dealt pocket aces that may very well hold up on the river.
Crystal Lake Mining is a sponsor.
As always, do your due diligence.
Happy Investing!
Dr. Kal Kotecha
TO JOIN OUR FREE NEWSLETTER PLEASE VISIT: WWW.JUNIORGOLDREPORT.COM AND WWW.STOCKTRENDSREPORT.COM
[1] https://www.crystallakeminingcorp.com/projects/listing/2/Newmont-Lake-Property/
Stock Trends Report/Junior Gold Report Newsletter and website: Stock Trends Report Newsletter/Junior Gold Report Newsletter and website is published as a copyright publication of Stock Trends Report/Junior Gold Report (STR). No Guarantee as to Content: Although STR attempts to research thoroughly and present information based on sources we believe to be reliable, there are no guarantees as to the accuracy or completeness of the information contained herein (newsletter and website). Any statements expressed are subject to change without notice. It may contain errors and you should not make any investment decisions based on what you have read on here. STR, its associates, authors, and affiliates are not responsible for errors or omissions. By accessing the site and receiving this email, you accept and agree to be bound by and comply with the terms and conditions as set out herein. If you do not accept and agree to the terms you should not use the Stock Trends Report site or accept this email. Consideration for Services: STR, it’s editor, affiliates, associates, partners, family members, or contractors have currently an interest or position in the Crystal Lake mining, as well as other sponsored companies which compensate STR. As such our opinions should be viewed as being biased. We hold options in and trade these stocks of the companies we profile and as such our opinions are biased. STR and its’ owner and affiliates/associates may buy/sell and trade the featured companies from time to time. STR has been paid by Crystal Lake Mining. Thus, multiple conflicts of interest exist. Therefore, information provided here within should not be construed as a financial analysis but rather as an advertisement. Conduct your own due diligence: The author’s views and opinions regarding the companies featured in report(s) are his/her own views and are based on information that he/she has researched independently and has received, which the author assumes to be reliable. You should never base any buying/selling/trading decisions off of our emails, newsletter, website, videos or any of our published materials. STR aims to provide information and often stock ideas but are by no means recommendations. The ideas and companies featured are highly speculative and you could lose your entire investment – consult a licensed financial advisor if you are considering investing in any of the featured companies. Subscribers/readers are encouraged to conduct their own research and due diligence. The companies mentioned are high risk and considered penny stocks that contain a high risk of volatility, therefore consult your investment advisor and do your own due diligence before purchasing. Never base any investment decision on information contained from our emails, newsletter, website, videos or any of our published materials. No Offer to Sell Securities: STR is not a registered broker dealer, investment advisor, financial analyst, stock picker, investment banker or other investment professional. STR is intended for informational, educational and research purposes only. It is not to be considered as investment advice. No statement or expression of any opinions contained in this report constitutes an offer to buy or sell the shares of the companies mentioned herein. Links: STR may contain links to related websites for stock quotes, charts, etc. STR is not responsible for the content of or the privacy practices of these sites. Information contained herein was extracted from public filings, profiled company websites, and other publicly available sources deemed reliable. Information in this report was taken on or before writing and dissemination and may not be updated. Do you own due diligence as information and events can and do change. Published reports may reference company websites or link to company websites and we disclaim and responsibility for the content and accuracy of any such information or website. Release of Liability: By reading the newsletter/website and/or watching videos by STR, you agree to hold STR, its associates, sponsors, affiliates, and partners harmless and to completely release them from any and all liabilities due to any and all losses, damages, or injuries (financial or otherwise) that may be incurred.
Forward Looking Statements
Except for statements of historical fact, certain information contained herein constitutes forward-looking statements. Forward looking statements are usually identified by the use of certain terminology, including “will”, “believes”, “may”, “expects”, “should”, “seeks”, “anticipates”, “has potential to”, or “intends’ or by discussions of strategy, forward looking numbers or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results or achievements to be materially different from any future results or achievements expressed or implied by such forward-looking statements. Forward-looking statements are statements that are not historical facts, and include but are not limited to, estimates and their underlying assumptions; statements regarding plans, objectives and expectations with respect to the effectiveness of the Company’s business model; future operations, products and services; the impact of regulatory initiatives on the Company’s operations; the size of and opportunities related to the market for the Company’s products; general industry and macroeconomic growth rates; expectations related to possible joint and/or strategic ventures and statements regarding future performance. Stock Trends Report does not take responsibility for the accuracy of forward looking statements and advises the reader to perform their own due diligence on forward looking numbers or statements.
- Published in Crystal Lake Mining, Mining, News Home